These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14654733)

  • 1. Costs of implementing recommendations on hypertension management given in recent guidelines.
    Zanchetti A
    J Hypertens; 2003 Dec; 21(12):2207-9. PubMed ID: 14654733
    [No Abstract]   [Full Text] [Related]  

  • 2. [Economy, costs and drug choices in cardiology. A reflection on the 2012 position paper of the Italian Society of Hypertension].
    Camerini F; Palcic S
    G Ital Cardiol (Rome); 2013 Jun; 14(6):412-5. PubMed ID: 23748537
    [No Abstract]   [Full Text] [Related]  

  • 3. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management.
    Hilleman DE
    J Manag Care Pharm; 2014 Jan; 20(1):93-100. PubMed ID: 24372463
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comment on IOWiG report plan. A medical decision may not be replaced].
    Vorstand der Deutschen Hochdruckliga E.V
    MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705
    [No Abstract]   [Full Text] [Related]  

  • 6. [The basic treatment of arterial hypertension (II). Pharmacological treatment].
    Pascual J; Orte L; Ortuño J
    Med Clin (Barc); 1994 Nov; 103(18):699-707. PubMed ID: 7808078
    [No Abstract]   [Full Text] [Related]  

  • 7. Keep the management of hypertension simple.
    Moser M
    J Clin Hypertens (Greenwich); 2004 Mar; 6(3):113-5. PubMed ID: 15010643
    [No Abstract]   [Full Text] [Related]  

  • 8. Health economic issues and the future treatment and management of hypertension.
    Giles TD
    AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost considerations in the drug treatment of hypertension. Is older better?
    Kaplan NM
    Pharmacoeconomics; 1996 Apr; 9(4):283-5. PubMed ID: 10160102
    [No Abstract]   [Full Text] [Related]  

  • 10. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension].
    Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA
    Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 12. New European, American and International guidelines for hypertension management: agreement and disagreement.
    Stergiou GS; Salgami EV; ; ;
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):359-68. PubMed ID: 15151482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension].
    Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L
    Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacoeconomic considerations in the management of hypertension.
    Pardell H; Tresserras R; Armario P; Hernández del Rey R
    Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH promotes use of lower cost drugs for hypertension.
    Spurgeon D
    BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic.
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):418. PubMed ID: 12419167
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antihypertensive treatment. Benefits and costs].
    Jensen HA; Svendsen TL
    Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacist-led hypertension disease management program cuts utilization and costs.
    Healthc Demand Dis Manag; 1997 Dec; 3(12):191-2. PubMed ID: 10176433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications.
    Simon SR; Rodriguez HP; Majumdar SR; Kleinman K; Warner C; Salem-Schatz S; Miroshnik I; Soumerai SB; Prosser LA
    J Clin Hypertens (Greenwich); 2007 Jan; 9(1):15-20. PubMed ID: 17215654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomical aspects of the use of beta-blockers in hypertension and heart failure].
    Ostroumova OD; Mamaev VI; Ishchenko KA; Shorikova EG
    Kardiologiia; 2003; 43(5):87-96. PubMed ID: 12942933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.